trending Market Intelligence /marketintelligence/en/news-insights/trending/tH0WPzG625i-8R_3GxVvbQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Kazia to sell remaining stake in Noxopharm for A$2.1M

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Kazia to sell remaining stake in Noxopharm for A$2.1M

Kazia Therapeutics Ltd. is selling its remaining stake in Noxopharm Ltd. through a single block trade for proceeds of about A$2.1 million.

The Sydney-based biotechnology company, which develops therapies for cancer, plans to use the proceeds for research and development.

Kazia, formerly known as Novogen, retains 3 million unlisted options in Noxopharm, which are exercisable at 80 cents each.

Kazia and Australia-based Noxopharm entered a collaboration in 2017 to develop the latter's cancer therapy NOX66. In return, Kazia agreed to take a small equity interest in Noxopharm.

The sale brings the total gross proceeds of Kazia's sale of its holding in Noxopharm to about A$2.4 million.